Blauvelt, A., Langley, R., Lebwohl, M., Strober, B., Warren, R., Puig, L., . . . Thaçi, D. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
Citación estilo ChicagoBlauvelt, A., et al. Bimekizumab Durability of Efficacy Through 196 Weeks and Safety Through 4 Years in Patients With Moderate to Severe Plaque Psoriasis: Results From the BE BRIGHT Open-label Extension Trial. 2025.
Cita MLABlauvelt, A., et al. Bimekizumab Durability of Efficacy Through 196 Weeks and Safety Through 4 Years in Patients With Moderate to Severe Plaque Psoriasis: Results From the BE BRIGHT Open-label Extension Trial. 2025.